News and Trends 23 Sep 2024 Vicebio and its molecular clamp vaccine raise big to tackle respiratory viruses Discover Vicebio’s molecular clamp technology as it completes a $100 million series B round for its bivalent vaccine against RSV and hMPV. September 23, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 17 Sep 2024 Estonia: Seven biotech companies to reckon with Explore Estonia’s biotech scene with 7 pioneering companies across Tallinn, Tartu, and beyond, fueled by top science parks and universities. September 17, 2024 - 7 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 16 Sep 2024 Vironexis’ AAV vector approach: The next frontier in cancer immunology? Delve into Vironexis’ launch with a pipeline of 10 cancer drug candidates built around its AAV vectors platform. September 16, 2024 - 6 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Podcast 13 Sep 2024Targeting inflammation: A revolution in disease treatment NLRP3 inflammasome-induced inflammation is at the root of nearly all disease pathologies. Listen to our conversation with Halia Therapeutics about it. September 13, 2024 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
News and Trends 12 Sep 2024 Biotech R&D crunch: The impact of the Inflation Reduction Act and economic challenges Delve into the consequences of the Inflation Reduction Act and the broader economic conditions on biotech R&D. September 12, 2024 - 7 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 11 Sep 2024 Can Europe revive its biopharma innovation leadership? Find out if the biotech runner-up, Europe, can step up to boost research and revive its innovation leadership. September 11, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2024 Psychedelic therapies under scrutiny: What’s next after Lykos’ MDMA rejection? Delve into the psychedelic-assisted therapy market and investors’ sentiment after the FDA’s decision about Lykos’ therapy. September 6, 2024 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 2 Sep 2024 Are we in an AI bubble? Biotech AI startups’ value plummet and leads to restructuration Delve into the downturn AI is experiencing in biotech: Is the bubble bursting or is the market correcting the high expectations? September 2, 2024 - 13 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Podcast 30 Aug 2024The future of combination vaccines To look at combination vaccines, listen to our conversation with Cesar Sanz Rodriguez, vice president, Europe & Switzerland, medical affairs, at Moderna. August 30, 2024 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
News and Trends 27 Aug 2024 Could microbiome drugs be the key to unlocking checkpoint inhibitors’ potential? As Microbiotica announces phase 1 approval for two microbiome drugs we delve into their potential in oncology and beyond. August 27, 2024 - 11 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Podcast 23 Aug 2024New German biotech spins out to develop radiotherapeutics While it is currently owned by the Eckert & Ziegler Group, Pentixapharm will soon be spun off as a separate company. Listen to our conversation with Andreas Eckert, founder of the company August 23, 2024 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
Best in Biotech 22 Aug 2024 Seven companies transforming the biotech industry in Italy Delve into Italy’s biotech landscape with seven companies that are leading the charge in the European country. August 22, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email